<DOC>
	<DOCNO>NCT01135992</DOCNO>
	<brief_summary>This trial conduct United States America ( USA ) . The aim clinical trial ass implication switch insulin glargine ( IGlar ) insulin degludec ( IDeg ) subject type 2 diabetes mellitus .</brief_summary>
	<brief_title>Switching From Insulin Glargine Insulin Degludec Subjects With Type 2 Diabetes Mellitus ( BEGINâ„¢ )</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Type 2 diabetes mellitus ( diagnose clinically ) least 6 month HbA1c maximum 10 % central laboratory analysis Current treatment basaloral therapy ( BOT ) ( prandial insulin ever ) consist : least three month insulin glargine daily ( average prescribe dose must unchanged ( within plus/minus 10 % ) four week prior Visit 1 confirm patient record verbal confirmation subject ) combination stable ( unchanged dos least 3 month prior Visit 1 ) OAD ( metformin , insulin secretagogues , pioglitazone , sitagliptin alphaglucosidaseinhibitor ) treatment approve ( accord label ) dose combination Use within last three month prior Visit 1 : Exenatide , Liraglutide Thiazoledinediones ( TZDs ) Pioglitazone Cardiovascular disease ( CVD ) define : stroke ; decompensated heart failure New York Heart Association ( NYHA ) class III IV ; myocardial infarction ; unstable angina pectoris ; coronary arterial bypass graft angioplasty within last six month prior Visit 1 Recurrent severe hypoglycaemia ( one severe hypoglycaemic episode last 12 month ) , hypoglycaemic unawareness judge Investigator , hospitalisation diabetic ketoacidosis previous six month Pregnancy , breastfeeding , intention become pregnant use adequate contraceptive measure accord local requirement Previous participation trial . Participation define started trial medication . Rescreening screen failure allow within limit recruitment period Known suspect hypersensitivity trial product relate product</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>